New combo aims to shield bone marrow in tough breast cancer

NCT ID NCT07255612

Not yet recruiting Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding trilaciclib to the chemotherapy drug eribulin can protect bone marrow in people with advanced triple-negative breast cancer who have already tried at least two chemotherapies. The study will enroll 29 participants and measure how often severe low white blood cell counts occur. The goal is to reduce dangerous side effects like infections and fatigue, helping patients stay on treatment longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trilaciclib and eribulin
What this could lead to: If it works, this could reduce severe side effects from chemotherapy, allowing patients to complete treatment more safely.
What could go wrong: This is a small, early-phase trial with only 29 participants, so results may not apply broadly. The drug combination may not work or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.